A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions

Hepatic ImpairmentHealthy

Interventions

DRUG

Tegoprazan 50mg

Oral administration once daily

Trial Locations (3)

RECRUITING

Gachon University Gil Medical Center, Incheon

RECRUITING

CHA Bundang Medical Center, Seongnam-si

RECRUITING

Samsung Medical Center, Seoul